New hope for kids with tough cancer: drug combo trial launches
NCT ID NCT07537400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug naxitamab to standard chemotherapy is safe and effective for children and young adults newly diagnosed with high-risk neuroblastoma, an aggressive nerve cell cancer. Ten participants aged 1 to 21 will receive the combination and be monitored for side effects and tumor response. The goal is to improve outcomes without increasing harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shaare Zedek Medical Center
Jerusalem, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••